Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MicroIslet, a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, has appointed Brian Conn as its new vice president of corporate finance and CFO.
Subscribe to our email newsletter
Mr Conn has served as a financial executive in high growth companies for over 20 years. Mr Conn has extensive experience with mergers and acquisitions and capital transactions.
Since 2000, Mr Conn has held executive positions, including CFO, with Chemicon International, Serologicals and Millipore. Mr Conn holds a BS in finance from Arizona State University.
Michael Andrews, CEO of MicroIslet, said: “Brian brings with him over twenty years of broad financial experience and his extensive knowledge will help strengthen the MicroIslet team as we move forward with our planned investigational new drug submission and first human dosing by year end.”